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Abstract
Background: Social determinants are known to be a driving force of health inequalities, even in high income
countries. Aim of our study was to determine if these factors can limit antiretroviral therapy (ART) access, outcome
and retention in care of people living with HIV (PLHIV) in Italy.
Methods: All ART naïve HIV+ patients (pts) of Italian nationality enrolled in the ICONA Cohort from 2002 to 2016
were included. The association of socio-demographic characteristics (age, sex, risk factor for HIV infection, educational
level, occupational status and residency area) with time to: ART initiation (from the first positive anti-HIV test), ART
regimen discontinuation, and first HIV-RNA < 50 cp/mL, were evaluated by Cox regression analysis, Kaplan Meier
method and log-rank test.
Results: A total of 8023 HIV+ pts (82% males, median age at first pos anti-HIV test 36 years, IQR: 29–44) were included:
6214 (77.5%) started ART during the study period. Women, people who inject drugs (PWID) and residents in Southern
Italy presented the lowest levels of education and the highest rate of unemployment compared to other groups.
Females, pts aged > 50 yrs., unemployed vs employed, and people with lower educational levels presented the lowest
CD4 count at ART initiation compared to other groups. The overall median time to ART initiation was 0.6 years (yrs)
(IQR 0.1–3.7), with a significant decrease over time [2002–2006 = 3.3 yrs. (0.2–9.4); 2007–2011 = 1.0 yrs. (0.1–3.9); 2012–
2016 = 0.2 yrs. (0.1–2.1), p< 0.001]. By multivariate analysis, females (p< 0.01) and PWID (p< 0.001), presented a longer time
to ART initiation, while older people (p< 0.001), people with higher educational levels (p< 0.001), unemployed (p= 0.02)
and students (p< 0.001) were more likely to initiate ART. Moreover, PWID, unemployed vs stable employed, and pts. with
lower educational levels showed a lower 1-year probability of achieving HIV-RNA suppression, while females, older patients,
men who have sex with men (MSM), unemployed had higher 1-year risk of first-line ART discontinuation.
Conclusions: Despite median time to ART start decreased from 2002 to 2016, socio-demographic factors still contribute to
disparities in ART initiation, outcome and durability.
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Background
Antiretroviral therapy (ART) is now recommended
worldwide for all people living with HIV (PLHIV),
regardless of their CD4 cell count [1]. However, barriers
to ART access for PLHIV do exist, with important
differences among countries, especially according to
socio-economic levels and organization models of na-
tional healthcare systems [2]. These disparities can affect
the probability of reaching the “90–90-90” target fixed
by UNAIDS for 2030 (90% diagnosed individuals of all
PLHIV, 90% treated patients, and 90% PLHIV achieving
viral suppression) [3].
Even in high income countries, social determinants are
known to be a driving force of health inequalities [4]. In
the setting of HIV infection, demographic and socioeco-
nomic factors can limit the access to testing, treatment,
and retention in care and, consequently, reduce survival
of PLHIV [5]. Entering the era of universal ART for all
HIV people living with HIV, we can hypothesize that
these factors could have an even greater impact on
disparities in ART access compared to past years.
In 2015, the proportion of people newly diagnosed with
HIV and presenting with < 200 cell/μL CD4 was 36.6% in
Italy, whereas proportion of people with CD4 < 350 cell/
μL was 54.5% [6]. In a previous study from the ICONA
(Italian Cohort Naïve Antiretrovirals) cohort, among
socio-demographic factors, migrant status was already
demonstrated to be associated with barriers to ART initi-
ation and with increased risk of treatment failure
compared to natives [7]. However, other social or behav-
ioral determinants, including gender [8, 9], poor education
[10, 11], unemployment [12], social exclusion within spe-
cial population groups, e.g. people who inject drugs
(PWID), need to be considered [13].
Moreover, also in people accessing ART and adhering to
therapy, lifestyle differences can affect chances to respond
to ART, occurrence of side effects and co-morbidities in
PLHIV [14].
Aim of our study was to determine if social determi-
nants influence ART access, outcome and retention in
care of PLHIV in spite of a context of public healthcare.
The knowledge of factors which define the “social vul-
nerability” can allow to allocate resources and plan for
interventions in order to reduce disparities which impact
survival of persons living with HIV.
Methods
The ICONA Foundation Study is an observational cohort
of people living with HIV who are antiretroviral naïve at
the time of enrolment. This cohort was set up in January
1997 and currently consists of over 14,000 patients from
50 Italian infectious disease reference units. Demographic
and socio-behavioral data, initiation and discontinuation
dates of each antiretroviral drug, HIV-viral load and CD4
cell count every 3–6 months, AIDS defining diseases ac-
cording to Centers for Disease Control and Prevention
(CDC) criteria as well as non-HIV related diseases and
death are recorded for all enrolled participants. Further
details are available at http://www.fondazioneicona.org/.
In the present study, all ART naïve PLHIV of Italian
nationality enrolled in the ICONA Cohort from 2002 to
2016 were included. The following socio-demographic
characteristics were retrieved and analyzed for their po-
tential association with the study endpoints: age, gender
(male, female), risk factor for HIV infection [heterosex-
uals (HS), men who have sex with men (MSM), people
who inject drugs (PWID)], educational level, occupa-
tional status and residency area. Taking into account the
structure of the Italian education system, and according
to the UNESCO/International Standard Classification of
Education standard classification (ISCED) [15], the
educational level was categorized into four categories:
primary school (corresponding to ISCED 0); junior sec-
ondary school (ISCED 1); high secondary school (ISCED
2–3); tertiary school (university and similar) (ISCED ≥4).
The occupational status was classified into seven categor-
ies as follows: full-time worker, temporary employed, self
employed, unemployed, student, retired, housewife (de-
fined as women only managing household affairs without
having paid employment). The residency area was catego-
rized in Northern, Central and Southern Italy.
Patients who did not attend visits for ≥18 months were
defined as lost to follow-up.
Statistical analysis
The study time was divided into 3–5 years periods:
2002–2006; 2007–2011; 2012–2016, in order to compare
different ART treatment period, according to guidelines
changes and progressive availability of new antiretroviral
drugs. Patients’ characteristics were compared according
to time period using Chi square test for trend for
categorical variables and Kruskal Wallis test for continu-
ous parameters.
Three different end-points were evaluated:
a) probability of ART initiation from the first positive
anti-HIV test;
b) virological response defined as first HIV-RNA < 50
cp/mL after therapy start;
c) first ART regimen discontinuation for any causes.
For the evaluation of the endpoints (b) and (c) only
patients with ≥1 year of follow-up were included.
The association of socio-demographic characteristics
(age, sex, risk factor for HIV infection, educational level,
occupational status and residency area, smoking habit) and
clinical parameters (CDC stage, CD4 and HIV RNA value
and pregnancy) with three end-points were evaluated by
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Cox regression analysis. 1-year probability was evaluated
by Kaplan Meier method and log-rank test was used to
compare survival curves.
Results
Baseline patient characteristics
A total of 8023 HIV-positive patients (82% males, me-
dian age at first positive anti-HIV test: 36 years, IQR:
29–44) were included in the ICONA observational data-
base in the period 2002–2016, whose characteristics are
shown in Table 1, overall and according to the three dif-
ferent study periods. Median age at time of enrolment,
proportion of males and MSM increased over time.
Moreover, a growing number of people with high second-
ary and tertiary level of education but a decreasing num-
ber of full employed workers was observed in last period
(2012–2016). The percentage of pre-treatment AIDS
events and very late presenter patients (< 200 CD4/μl) de-
creased passing from the first to the last period from 13
and 26% to 7 and 17%, respectively.
The distribution of educational level and occupational
status according to gender, mode of HIV transmission
and area of residency are shown in Fig. 1. Women,
PWID and residents in Southern Italy presented the
lowest levels of education and the highest rate of un-
employment compared to other groups.
The median CD4 cell count at time of enrolment in
the ICONA cohort according to the investigated
socio-demographic variables is summarized in Table 2
In particular, women, people who acquired the HIV in-
fection through heterosexual contacts, older individuals,
and housewives, were more at risk of late presentation.
Moreover, the risk of late presentation decreased with
increasing educational level.
The number of lost to follow-up patients according to
the main study variables is reported in Table 3; female
gender, younger age, PWID, low educational level and un-
employment were associated with a higher drop-out rate.
Time to ART initiation
A total of 6214 cohort participants (77.5%) started
ART during the study period after a median time to
ART initiation of 0.6 years (IQR 0.1–3.7). The median
of years from first HIV test and cART initiation de-
crease over time [2002–2006 = 3.3 years (0.2–9.4);
2007–2011 = 1.0 years (0.1–3.9); 2012–2016 = 0.2 years
(0.1–2.1), p < 0.001].
Median CD4 cell count levels at time of ART initiation
are also showed in Table 2. Females, patients aged > 50 years,
housewife and retired, and people with lower educational
levels presented the lowest CD4 count at ART initiation
compared to other groups.
Factors associated with the probability of ART initi-
ation by multivariable analysis are reported in Fig. 2:
females vs. males, PWID compared to HS showed a
reduced probability of starting therapy. On the other
hand, unemployed people and students compared to
full time workers, older people, people with higher
educational levels, and residents in the Central and
Southern area of the country were more likely to
initiate ART.
Response to ART
A total of 5792 patients starting ART during the
study period presented at least 1 year of follow-up
and were included in the analysis on the response to
ART. 5111 (88.2%) cohort participants reached at
least one HIV-RNA < 50 cp/mL. After adjustment for
potential confounders, intravenous drug use compared
to heterosexual as mode of HIV transmission, un-
employment and temporary employment vs full time
work, and residency in Southern and Central vs
Northern Italy were associated with a lower probabil-
ity of achieving HIV-RNA suppression. On the con-
trary, patients with higher educational levels (high
school or university, ISCED 2–4) were more likely to
reach an undetectable viral load than their counter-
parts (Fig. 3).
ART discontinuation
A total of 3079 out of 5792 patients (53%) changed or
interrupted first line-regimen during the study period.
In Fig. 4, factors associated with first-line ART discon-
tinuation by multivariable analysis are summarized.
MSM presented a higher risk of first-line ART discon-
tinuation along with patients aged 40–50 and more
than 50 years vs < 30, females vs males, unemployed
people compared to full time workers. On the contrary,
housewives and residents in Central and Southern Italy
presented a lower rate of therapy discontinuation than
other groups, while no association was observed be-
tween educational level and therapy interruption.
Discussion
Socio-demographic factors are an important cause of
health inequalities, even in high income countries adopt-
ing universal health care systems [5]. In Italy, both HIV
testing and ART are free of charge for all individuals, in-
dependently on disease stage, work conditions or other
economical issues. Data from the national health insti-
tute demonstrated a satisfactory framework of the HIV
treatment cascade in our country, which appears to be
very close to WHO targets, showing that in 2014 92% of
people diagnosed with HIV were in ART treatment,
87.7% of whom with suppressed HIV viremia [6]. Ac-
cording to changes in international and national guide-
lines, which progressively suggested to start ART at
higher CD4 count overtime, our data demonstrate that,
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Table 1 Socio-demographic characteristics of patients according to years of starting cART or year of last observation
Overall
N = 8023
2002–2006
N = 1543
2007–2011
N = 2166
2012–2016
N = 4314
p
Gender, n (%)
Female 1434 (17.9%) 453 (29.4%) 368 (17.0%) 613 (14.2%) < 0.001
Male 6589 (82.1%) 1090 (70.6%) 1798 (83.0%) 3701 (85.8%)
Age at first positive anti-HIV test, n (%)
< 30 2582 (32.2%) 682 (44.2%) 637 (29.5%) 1263 (29.3%) < 0.001
30–40 2646 (33.0%) 521 (33.8%) 742 (34.4%) 1383 (32.1%)
40–50 1709 (21.3%) 221 (14.3%) 475 (22.0%) 1013 (23.5%)
> 50 1079 (13.5%) 119 (7.7%) 305 (14.1%) 655 (15.2%)
Mode of HIV transmission, n (%)
HS 2773 (34.6%) 590 (38.2%) 816 (37.7%) 1367 (31.7%) < 0.001
PWID 1131 (14.1%) 509 (33.0%) 265 (12.2%) 357 (8.3%)
MSM 3528 (44.0%) 342 (22.2%) 942 (43.5%) 2244 (52.0%)
other/unknown 591 (7.4%) 102 (6.6%) 143 (6.6%) 346 (8.0%)
Education
Elementary school 362 (4.5%) 162 (10.5%) 99 (4.6%) 101 (2.3%) < 0.001
Junior high school 1803 (22.5%) 596 (38.6%) 528 (24.4%) 679 (15.7%)
High school 2576 (32.1%) 423 (27.4%) 708 (32.7%) 1445 (33.5%)
University 920 (11.5%) 101 (6.6%) 217 (10.0%) 602 (14.0%)
Missing data 2362 (29.4%) 261 (16.9%) 614 (28.4%) 1487 (34.5%)
Employement
Full time worker 3575 (44.6%) 703 (45.6%) 1100 (50.8%) 1772 (41.1%) < 0.001
Unemployed 910 (11.3%) 307 (19.9%) 217 (10.0%) 386 (9.0%)
Self employed 1231 (15.3%) 265 (17.2%) 304 (14.0%) 662 (15.4%)
Temporary employed 192 (2.4%) 75 (4.9%) 45 (2.1%) 72 (1.7%)
Student 296 (3.7%) 29 (1.9%) 75 (3.5%) 192 (4.5%)
Retired 256 (3.2%) 40 (2.6%) 96 (4.4%) 120 (2.8%)
Housewife 233 (2.9%) 103 (6.7%) 72 (3.3%) 58 (1.3%)
Other/unknown 204 (2.5%) 18 (1.2%) 40 (1.9%) 146 (3.4%)
Missing data 1126 (14.0%) 3 (0.2%) 217 (10.0%) 906 (21.0%)
Residency area
Northern Italy 4540 (56.6%) 763 (49.5%) 1226 (56.6%) 2551 (59.1%) < 0.001
Central Italy 2678 (33.4%) 517 (33.5%) 769 (35.5%) 1392 (32.3%)
Southern Italy 805 (10.0%) 263 (17.0%) 171 (7.9%) 371 (8.6%)
Smokers
No 3589 (44.7% 532 (34.5%) 1040 (48.0%) 2017 (46.8%) < 0.001
Yes 3636 (45.3%) 787 (51.0%) 990 (45.7%) 1859 (43.1%)
Not known 798 (10.0%) 224 (14.5%) 136 (6.3%) 438 (10.2%)
CDC stage
C 714 (8.9%) 199 (12.9%) 219 (10.1%) 296 (6.9%) < 0.001
A/B 7309 (91.1%) 1344 (87.1%) 1947 (89.9%) 4018 (93.1%)
Pre treatment CD4 cell/mmc
< =200 1630 (20.3%) 404 (26.2%) 508 (23.5%) 718 (16.6%) < 0.001
201–350 1952 (24.3%) 516 (33.4%) 699 (32.3%) 737 (17.1%)
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for patients enrolled in the ICONA cohort, time to ART
initiation significantly decreased from more than 3 years
in 2002–2006 up to 0.2 years in the last 4 years. In this
context, we aimed to evaluate if social determinants do
still play a role in access and response to antiretroviral
therapy in PLHIV.
Herein, we limited our analysis to native Italian people
in order to avoid that confounding factors related to the
status of migrant could influence our results, including
language barriers and cultural differences. In a previous
paper, however, including patients enrolled in the
ICONA cohort as well, an increased risk of both delayed
access to ART and virological failure was already demon-
strated in migrants living with HIV [7]. Moreover, only
patients enrolled in ICONA during a relative recent
period (2002–2016) were included in the present study,
in order to take into account exclusively modern (and
highly potent) antiretroviral regimens.
The results of our analysis clearly evidenced that, even
in a country with universal health care coverage as Italy,
several social determinants, including female gender,
PWID as a risk factor for HIV transmission, low educa-
tional level and unemployment, significantly impact both
ART access and outcomes. It should be underlined that
these variables are also strictly interconnected to each
other: in fact, females, PWID and residents in Southern
Italy also presented the lowest level of education and the
highest rate of unemployment. Although the public
health system is freely assured throughout the country
since 1978, after a constitutional reform voted in 2001,
budget and organization of health services are under re-
gional control. Therefore, many differences in health ser-
vices may exist among different Italian areas. Based on
historical reasons, Northern, Central, and Southern Italy
are quite different from an economic and social point of
view, with a North-to-South gradient, being in general
Table 1 Socio-demographic characteristics of patients according to years of starting cART or year of last observation (Continued)
Overall
N = 8023
2002–2006
N = 1543
2007–2011
N = 2166
2012–2016
N = 4314
p
351–500 1761 (22.0%) 251 (16.3%) 473 (21.8%) 1037 (24.0%)
500-max 1913 (23.8%) 308 (20.0%) 291 (13.4%) 1314 (30.5%)
Missing data 767 (9.6%) 64 (4.2%) 195 (9.0%) 508 (11.8%)
Pre treatment log10 HIV RNA
< 4 1844 (23.0%) 385 (25.0%) 427 (19.7%) 1032 (23.9%) 0.012
4–4.7 1961 (24.4%) 379 (24.6%) 524 (24.2%) 1058 (24.5%)
4.8–5.2 1644 (20.5%) 363 (23.5%) 478 (22.1%) 803 (18.6%)
5.2+ 1590 (19.8%) 316 (20.5%) 488 (22.5%) 786 (18.2%)
Missing data 984 (12.3%) 100 (6.5%) 249 (11.5%) 635 (14.7%)
Pregnancy status
Not pregnant 7715 (96.2%) 1517 (98.3%) 2109 (97.4%) 4089 (94.8%) < 0.001
Pregnant 30 (0.4%) 5 (0.3%) 7 (0.3%) 18 (0.4%)
Missing data 278 (3.5%) 21 (1.4%) 50 (2.3%) 207 (4.8%)
Fig. 1 Distribution of education level (a) and occupational status (b) according to gender, mode of HIV transmission and area of residency
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Northern regions the most industrialized areas of the
nation.
First, a risk of late presentation was demonstrated for
all the above mentioned categories, which was particu-
larly evident for people aged more than 50 years, which
is in line with national and international reports [6, 16].
Similarly, older patients started ART with significantly
lower CD4 cell number compared to younger subjects
and, in parallel, they presented significantly longer time
to ART initiation since the first anti-HIV positive test.
People > 50 years old had the same mode of HIV acqui-
sition of younger people, but they may be less aware of
their HIV status. Moreover, HIV testing is probably less
recommended by health care providers in this group
than in young adults [17]. However, old people need to
be recognized as a high risk group as they present
Table 2 Median CD4 cell count at time of enrolment in the ICONA cohort and at time of ART initiation according to socio-
demographic characteristics
CD4 at enrollment CD4 at time of ART initiation
Median IQR p Median IQR p
n/mmc n/mmc n/mmc n/mmc
Gender
Male 439 260–621 0.453 360 223–520 < 0.001
Female 448 263–635 325 205–479
Age (years)
< 30 511 364–696 < 0.001 390 273–563 < 0.001
30–40 440 269–622 358 225–514
40–50 377 188–554 323 173–483
> 50 283 108–500 273 105–422
Mode of HIV transmission
HS 385 191–580 < 0.001 310 171–460 < 0.001
PWID 482 305–685 342 222–530
MSM 471 310–643 390 267–550
Residency area
North 499 336–694 < 0.001 333 232–460 < 0.001
Centre 443 270–634 302 193–436
South 432 248–646 330 205–516
Education
Elementary school 384 179–606 < 0.001 288 156–430 < 0.001
Junior high school 437 232–624 320 197–481
High school 438 261–613 353 224–505
University 464 299–637 393 272–569
Employement
Unemployed 439 264–644 < 0.001 342 216–523 < 0.001
Full time worker 450 279–626 351 225–506
Self employed 437 249–621 351 222–510
Temporary employed 467 320–650 340 220–506
Student 540 385–700 443 325–648
Retired 326 131–534 274 121–440
Housewife 390 157–590 302 122–427
Year of ART initiation/last observation
2002–2006 465 278–661 < 0.001 292 185–448 < 0.001
2007–2011 385 232–554 305 196–409
2012–2016 460 270–637 414 262–574
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poorer immunologic response compared with younger
patients, with higher mortality rates [18]. In our study,
ART initiation was more likely with increasing age, even
after adjustment for CD4 count. No significant associ-
ation between age and achievement of viremia suppres-
sion on ART after 1 year was demonstrated. Older
patients were associated with a more recent year of ART
initiation, which was conversely associated with lower
risk of discontinuation. From the multivariable ana-
lysis, however, after adjusting for year of ART
initiation, older age was related to a higher risk of
therapy discontinuation, probably due to a higher fre-
quency of side effects and co-morbidities in this
patient group. The type of drug ART regimen could
also be a possible explanation, as older individuals
were more frequently on a protease inhibitor-based
regimen (42% compared to 25% in patients aged > 30 years,
data not shown).
If female gender is a risk factor for late presentation,
delayed therapy initiation and poor ART response is
controversial in literature [19–21]. In fact, several
aspects might contribute to confound results from dif-
ferent cohorts, also depending on the chosen endpoints
[19]: firstly, early diagnosis of HIV infection in women is
favored by screening programs for HIV during preg-
nancy; secondly, lower HIV-RNA levels have been ob-
served in women compared to males [20] which could
justify better response rates to ART. Finally, regarding
the association of gender and mortality for PLHIV, it
should be taken into account that women have an over-
all higher life expectancy compared to men, at least in
Western countries. Moreover, in PLHIV, a lower inci-
dence of non-AIDS events in women compared to males
has been described [22]. In our study, after controlling
for other variables including pregnancy status and HIV
viremia levels, females resulted more at risk of delayed
ART initiation and therapy discontinuation, even if no
differences in response rates to the first year of ART
were evidenced. The status of housewife, however, was
not associated with the same endpoints in our analysis;
on the contrary, they presented a lower rate of therapy
discontinuation. No data regarding this association in
literature are available to our knowledge.
Among the different risk group categories for HIV
acquisition, as expected, people who inject drugs pre-
sented a delay in initiation of ART and inferior viro-
logical response to therapy; our results are in agreement
with the paper of Lesko et al. [13] who demonstrated as
PWID, even in recent years, spent a significantly larger
amount of time not on ART compared with non-PWID
or, when on ART, not virally suppressed, thus greatly
contributing to HIV transmission. On the contrary,
MSM, who became the most represented group in the
last years (52%), initiated ART at significantly higher
CD4 levels than other risk groups; however, MSM
resulted more frequently at risk of ART change / inter-
ruption compared to other groups.
The economic status of PLHIV is always hard to be
determined. Educational level and occupational status,
however, can be considered good proxies of such con-
dition [5]. We demonstrated that the educational level
has a crucial role of in influencing both access and
response to ART in our country. This finding extend
previous observations in Italy [23] and in other
Table 3 Drop-out rate according to socio-demographic
characteristics
N° of lost to follow-up P
Gender
Male 1373 (20.8%) < 0.001
Female 423 (29.5%)
Age at first positive anti-HIV test
< 30 797 (30.9%) < 0.001
30–40 566 (21.4%)
40–50 258 (15.1%)
> 50 168 (15.6%)
Mode of HIV transmission
HS 571 (20.6%) < 0.001
PWID 552 (48.8%)
MSM 530 (15.0%)
other/unknown 143 (24.2%)
Residency area
North 929 (20.5%) < 0.001
Centre 560 (20.9%)
South 307 (38.1%)
Education
Elementary school 141 (39.0%) < 0.001
Junior high school 574 (31.8%)
High school 484 (18.8%)
University 129 (14.0%)
Missing 468 (19.8%)
Employment
Unemployed 755 (21.1%) < 0.001
Full time worker 347 (38.1%)
Self employed 264 (21.4%)
Temporary employed 72 (37.5%)
Student 67 (22.6%)
Retired 50 (19.5%)
Housewife 94 (40.3%)
other/unknown 33 (16.2%)
missing data 114 (10.1%)
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European countries [24–26], and are in agreement
with recent multi-cohort data from the COHERE [10,
11]. In addition, the relationship between occupational
status and ART access and outcomes was also ana-
lyzed. Very few studies [12, 27] have addressed this
point to date, as this information is not registered in
the most part of the cohorts enrolling HIV patients.
In France [27], a global indicator of social vulnerabil-
ity including education, employment, and housing sta-
bility and comfort, after adjustment for lifestyle
factors, psychosocial characteristics (depression, drug
using) and known biomedical factors, was associated
with mortality in PLHIV. Moreover, unemployment
was associated with a reduced sustained virological
suppression (e.g. undetectable viral load for
≥6 months) [12]. In our analysis, unemployment was
associated with all three endpoints (a longer time to
ART initiation, lower chances to reach a suppressed
HIV viremia, and higher risk of discontinuation). It
must be underlined that work conditions, although
considered an excellent proxy of economic status,
may change during patient’s life and cannot be con-
sidered as an independent variable as a poor health
status could also cause job loss. However, as only the
first year ART response was investigated in the
present study, and the occupational status was regis-
tered at entry in the cohort, our results can be con-
sidered reliable.
Fig. 2 Multivariable model of factors associated with time to cART start (adjusted for CD4 count, viral load, pregnancy status, smoking)
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Among lifestyle factors, smoking was not associated
with any of the study endpoints in our analysis [14].
All results were adjusted for smoking and pregnancy
status. However, other behavioral and clinical factors,
including alcoholism or depression, were not targeted
in our analysis but could have indirectly influenced
our results. In particular, the inclusion of mental
health outcomes as part of the ICONA database in
the future would be suitable. A high percentage of
missing data regarding educational level could have
introduced some biases, representing an important
limitation of our study. A major limitation is also the
lack of information regarding the presence of trans-
gender people in our cohort. In fact, even if sexual
orientation and gender identity should be reported
the ICONA database, no transgender cohort partici-
pants were registered among patients fulfilling
inclusion criteria in our study, which seems to sug-
gest that this information was under-reported by
clinicians [28, 29].
Conclusions
In conclusions, notwithstanding median time to ART
start decreased from 3.3 to 0.2 years from 2002 to 2016,
Fig. 3 Multivariable model of factors associated with virological response (HIV RNA < 50) (adjusted for CD4 count, viral load, pregnancy status, smoking)
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socio-demographic factors still contribute to important
disparities in ART initiation, outcome and durability in
PLHIV from Italy. Therefore, a deeper evaluation of
socio-economic determinants, possibly using a standardized
approach, is needed on one side; on the other side,
welfare interventions aiming to reduce the social
inequality for fragile populations such as PWID,
women, old people, patients with low educational
level and unemployed, along with migrants, would in-
directly improve the cascade of care for PLHIV.
Moreover, it should be underlined that relatively few
complete national data regarding continuum of care
are available in Italy as in other countries, with wide
variation in reporting procedures [30]. Nowadays it
becomes more and more important to use consistent
and accurate methods for tracking progress towards
the achievement of WHO 90–90-90 targets.
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